162 related articles for article (PubMed ID: 29874982)
1. Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer.
Yang J; Pyo JS; Kang G
Int J Biol Markers; 2018 Jun; ():1724600818772194. PubMed ID: 29874982
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis.
Pyo JS; Kang G; Cho WJ; Choi SB
Pathol Res Pract; 2016 Aug; 212(8):710-6. PubMed ID: 27465837
[TBL] [Abstract][Full Text] [Related]
3. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
Pyo JS; Kang G; Sohn JH
Int J Biol Markers; 2016 Dec; 31(4):e413-e421. PubMed ID: 27338643
[TBL] [Abstract][Full Text] [Related]
4. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
5. Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.
Ko YS; Kim NY; Pyo JS
Int J Biol Markers; 2018 Jan; 33(1):49-54. PubMed ID: 28478639
[TBL] [Abstract][Full Text] [Related]
6. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
[TBL] [Abstract][Full Text] [Related]
7. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.
Zhiwei W; Yuan J; Yihui Y; Xin H; Jingtao C; Lei S; Yongjian D
Thorac Cancer; 2017 Sep; 8(5):471-476. PubMed ID: 28742247
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
Wang W; Cheng G; Zhang G; Song Z
Lung Cancer; 2020 Aug; 146():224-229. PubMed ID: 32580101
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas.
Thurfjell V; Micke P; Yu H; Krupar R; Svensson MA; Brunnström H; Lamberg K; Moens LNJ; Strell C; Gulyas M; Helenius G; Yoshida A; Goldmann T; Mattsson JSM
Transl Lung Cancer Res; 2022 Dec; 11(12):2477-2494. PubMed ID: 36636421
[TBL] [Abstract][Full Text] [Related]
10. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Different
Dülger O; Öz B
Balkan Med J; 2023 Sep; 40(5):344-350. PubMed ID: 37318131
[TBL] [Abstract][Full Text] [Related]
12. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of patients with
Bi H; Ren D; Ding X; Yin X; Cui S; Guo C; Wang H
Transl Cancer Res; 2020 Jul; 9(7):4383-4392. PubMed ID: 35117804
[TBL] [Abstract][Full Text] [Related]
14. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
[TBL] [Abstract][Full Text] [Related]
15. A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer.
Hofman V; Goffinet S; Bontoux C; Long-Mira E; Lassalle S; Ilié M; Hofman P
J Pers Med; 2023 May; 13(5):. PubMed ID: 37240980
[TBL] [Abstract][Full Text] [Related]
16. Histologic and Molecular Characterization of Non-Small Cell Lung Carcinoma With Discordant ROS1 Immunohistochemistry and Fluorescence In Situ Hybridization.
Wilcock DM; Schmidt RL; Furtado LV; Matynia AP; Deftereos G; Sirohi D
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):19-26. PubMed ID: 34534989
[TBL] [Abstract][Full Text] [Related]
17. Correlation of
Sharma S; Mishra SK; Bhardwaj M; Jha S; Geller M; Dewan A; Jain E; Dixit M; Jain D; Munjal G; Kumar S; Mohanty SK
South Asian J Cancer; 2022 Jul; 11(3):249-255. PubMed ID: 36588618
[TBL] [Abstract][Full Text] [Related]
18. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review.
Pyo JS; Sohn JH; Kang G
Pathol Oncol Res; 2016 Oct; 22(4):831-7. PubMed ID: 27197524
[TBL] [Abstract][Full Text] [Related]
20. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
